Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7K88

Crystal structure of bovine RPE65 in complex with hexaethylene glycol monooctyl ether

Summary for 7K88
Entry DOI10.2210/pdb7k88/pdb
DescriptorRetinoid isomerohydrolase, FE (II) ION, 3,6,9,12,15,18-hexaoxahexacosan-1-ol, ... (6 entities in total)
Functional Keywordsnon-heme iron, isomerohydrolase, c8e6, inhibitor, beta-propeller, isomerase, hydrolase-inhibitor complex, hydrolase/inhibitor
Biological sourceBos taurus (Bovine)
Total number of polymer chains2
Total formula weight122988.07
Authors
Kiser, P.D. (deposition date: 2020-09-26, release date: 2021-06-02, Last modification date: 2024-10-30)
Primary citationBlum, E.,Zhang, J.,Zaluski, J.,Einstein, D.E.,Korshin, E.E.,Kubas, A.,Gruzman, A.,Tochtrop, G.P.,Kiser, P.D.,Palczewski, K.
Rational Alteration of Pharmacokinetics of Chiral Fluorinated and Deuterated Derivatives of Emixustat for Retinal Therapy.
J.Med.Chem., 64:8287-8302, 2021
Cited by
PubMed Abstract: Recycling of all--retinal to 11--retinal through the visual cycle is a fundamental metabolic pathway in the eye. A potent retinoid isomerase (RPE65) inhibitor, ()-emixustat, has been developed and tested in several clinical trials; however, it has not received regulatory approval for use in any specific retinopathy. Rapid clearance of this drug presents challenges to maintaining concentrations in eyes within a therapeutic window. To address this pharmacokinetic inadequacy, we rationally designed and synthesized a series of emixustat derivatives with strategically placed fluorine and deuterium atoms to slow down the key metabolic transformations known for emixustat. Crystal structures and quantum chemical analysis of RPE65 in complex with the most potent emixustat derivatives revealed the structural and electronic bases for how fluoro substituents can be favorably accommodated within the active site pocket of RPE65. We found a close (∼3.0 Å) F-π interaction that is predicted to contribute ∼2.4 kcal/mol to the overall binding energy.
PubMed: 34081480
DOI: 10.1021/acs.jmedchem.1c00279
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.1 Å)
Structure validation

239149

数据于2025-07-23公开中

PDB statisticsPDBj update infoContact PDBjnumon